RBR-1047fwbfActive, not recruitingPhase 1
Pilot study to verify the safety and efficacy of Doxycycline in the treatment of levodopa-induced dyskinesias in patients with Parkinson's disease
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo0 sitesStarted: May 12, 2022Last updated:
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Intervention
Eligibility Criteria
- Ages
- 18Y to 0 (—)
Inclusion Criteria
- •Patients 18 years of age or older; diagnosed with Parkinson's disease according to the United Kingdon Parkinson's Disease Society Brain Bank clinical diagnostic criteria; presenting at the initial evaluation with at least some functional impact dyskinesias (score higer than1 on item 4. 2 of the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS); who are using levodopa at least three times a day; and who can keep doses of antiparkinsonian medications unchanged for at least four weeks prior to screening and during study participation.
Exclusion Criteria
- •Diagnosis of atypical or secondary parkinsonism; treatment of any experimental drug or other intervention within 90 days prior to screening or baseline assessment; presence of moderate or severe psychotic symptoms (score greater than 2 on item 1. 2 of the Movement Disorders Society's Unified Scale for Assessment of Parkinson`s disease; diagnosis of dementia according to the Movement Disorders Society diagnostic criteria; suffering from serious systemic conditions (infections, malignancies, chronic kidney or liver disease); pregnancy or lactation; history of hypersensitivity or allergic reaction to tetracyclines; absence of clinical dyskinetic movements at baseline assessment.
Investigators
Similar Trials
Recruiting
Phase 2
Pilot cml autograft/glivec (STI571)/Intron A trialAdvanced phase chronic myeloid leukaemiaPh-positive acute lymphoblastic leukemiaCancer - Leukaemia - Acute leukaemiaACTRN12605000071628Australasian Leukaemia and Lymphoma Group48
Unknown
Phase 2
Phase 2 study of DS-8500aType 2 Diabetes MellitusJPRN-jRCT2080222546DAIICHISANKYO Co.,Ltd.90
Completed
Not Applicable
Combination therapy of Visudyne, Minocycline, Dexamethasone and Ranibizumab (VIMDER) for the treatment of subfoveal choroidal neovascularisation (CNV)Age-related macular degenerationISRCTN34410935King's College Hospital NHS Foundation Trust (UK)20
Completed
Not Applicable
A pilot study to examine the safety and efficacy of posterior juxta-scleral (80 mg) triamcinolone acetonide, administration, in addition to Visudyne (verteporfin) photodynamic therapy for predominantly classic choroidal neovascularisation secondary to age-related macular degeneration: an open-label, randomised, active controlled trialISRCTN33957677King's College Hospital (UK)80
Completed
Not Applicable
To determine the safety and effectiveness of Dandruff ControlOil Shots in dandruff reduction in Healthy Adult HumanSubjects with Dandruff on the scalpCTRI/2022/04/041701Brillare Science Private Limited16